Connect with us


These Marijuana Stocks (OTCMKTS:THCZ) Could Finish The Year On A High Note



Over the weekend, lawmakers approved a measure to put up a barrier to the Justice Department from going after states where pot is legal for health reasons, IE medical marijuana. The $1 trillion spending bill included a plan to stop the Justice Department from spending any money to enforce a federal ban on growing or selling marijuana in states that have moved to legalize pot for medical use. As Congress shifts its views and America comes one step closer to state and federal autonomy, several stocks in the marijuana sector have found themselves hitting new “highs” in December.


Totally Hemp Crazy Inc. (OTCMKTS:THCZ) has employed Rhino Marketing as its selected marketing firm to roll out its hemp infused beverage products.  Rhino has most notably worked on major international product launches and fast moving consumer retail products such as Wolfgang Puck Iced Coffee, Nissan, and the National Football League. Red Bull (that wing giving company) is also on Rhino’s record and for such a lofty firm like this working to launch a niche product like THCZ’s hemp infused products should speak volumes for the Company itself.


In recent weeks, THCZ has announced that upon completion of the pilot markets, the retail rollout will go nationwide with the expectation that the cans will be produced and ready to be shipped to the bottling company by January.


Over the course of December, Totally Hemp Crazy share price has been mixed with recent activity suggesting a new upward movement in price.  Since Tuesday’s open, shares of THCZ have increased in value by as much as 32% to highs of $0.0099 on Wednesday.


Electronic Cigarettes International Group, Ltd. (OTCMKTS:ECIG) announced on Monday that its subsidiary, VIP®, opened its first dedicated ‘Blending Boutique’ located in East London, which is actually the first of its kind in the UK.  The shop allows customers to blend their own e-liquid flavor and even offers an on-hand expert mixologist to help during the process.  To the surprise of traders, the Monday session took an unexpected turn with the stock plummeting over 50% during the trading day to settle out at $0.0581.


However, as many other vape companies saw on Tuesday, the increased attention on the sector hit a fever pitch and ECIG shares jumped to highs of $0.117 before settling out the day at $0.1105.  This marked a rebound in the stock by more than 100% during the 2-day swing. Though ECIG is still trading near its 52-week low, the stock has seen an increase in daily liquidity and may be starting to finally see some “light at the end of the tunnel” heading into the remainder of the year.


Hemp, Inc. (OTCMKTS:HEMP) announced on Tuesday that the Company will be one of the major sponsors at the 1st Annual “Cultural Creatives” Ascent Expo in Los Angeles, CA this coming February.  “Hemp, Inc. is proud to continue our commitment to corporate consciousness, environmentalism, philanthropy and personal empowerment through our sponsorship of the 2015 Ascent Expo,” says Bruce Perlowin, CEO of Hemp, Inc. “This is the 1st Annual Ascent Expo and we anticipate many new innovative products and successful joint ventures. The Industrial Hemp and Medical Marijuana industries are definitely one of the subsets of the ‘Cultural Creatives’ movement which we will be showcasing in the ‘Hemp Zone’ at the Expo.”


Over the last three months, shares of HEMP have seen prices as high as $0.0625.  During the month of December, price movement has been relatively static as a new sideways trend holds the market between $0.03-$0.04.  This recent pull back from highs may have been a reaction (in the short term) to the company’s announcement in November that it will be refocusing the company’s mission on being the premier leader in industrial hemp processing


It’s very hard to ignore the recent momentum that the marijuana market has begun to gain over the last year.  From vaporizers to edible treats, there is no shortage of opportunity within the industry.  Heading into the end of America’s first year of marijuana legalization, there’s certainly been a lot learned and appears to be a lot more in store as 2015 begins to ramp up.


ABOUT US: monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.


Timing is everything when trading Penny Stocks. Subscribe to the newsletter and start receiving daily alerts.

Subscribe Here:



Legal Disclaimer


Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. EGM FIRM INC which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. EGM FIRM INC which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. EGM FIRM INC which owns, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.





Company: EGM FIRM INC.
Contact Name: Adam Heimann
Contact Email:


CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement




Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading


These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?




Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading


ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week



Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here
JOIN US NOW: For Details Contact us at

Or You can send me a friend request on facebook here

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at

Continue Reading